Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Q1 Earnings Review: Healthy Revenue Increases, Smaller Profit Growth

publication date: May 23, 2011
It's earnings season, and almost every day for the past few weeks, one to three China life science companies listed in the US have released their quarterly financial reports. Taken as a whole, companies from this sector have almost uniformly reported higher revenues. Net income has also risen, though usually by a lower percentage. The two largest companie in the groups, Mindray Medical and WuXi PharmaTech, continue to impress with strong gains. Price/Earnings ratios are lower than they were a few years ago, ranging from 31 down to a lowly 1.4. We give snapshots of the sixteen companies that have released reports so far this month. More details....

Stock Symbols: (NYSE: MR) (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital